Zemocimig for hemophilia a

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Feb 2026: Trial registered, NCT07416604
  2. 27 Apr 2026: Trial started, NCT07416604

The trials

NCT07416604: A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

State
Under way
Phase
Phase 3
People
360 planned
Started
27 Apr 2026
Primary completion
29 Feb 2028
Arms
Main Study Treatment Period: NXT007 Prophylaxis, Open-Label Extension Period: NXT007 Prophylaxis
Results
None posted
  1. 18 Feb 2026: Trial registered
  2. 27 Apr 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as NXT007.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.